1. Novel biologically active series of N-acetylglucosamine derivatives for the suppressive activities on GAG release
- Author
-
Yuan Li, Ying Li, Cao Tingting, Shu-Fan Yin, Dong Lin, Jiang Lijuan, and Li Yong
- Subjects
Osteoarthritis ,Biochemistry ,Acetylglucosamine ,Analytical Chemistry ,03 medical and health sciences ,chemistry.chemical_compound ,Chondrocytes ,0302 clinical medicine ,Glucosamine ,medicine ,N-Acetylglucosamine ,Animals ,Humans ,Isoxazole ,Cells, Cultured ,Glycosaminoglycans ,030203 arthritis & rheumatology ,Molecular Structure ,Organic Chemistry ,Biological activity ,General Medicine ,medicine.disease ,Bioavailability ,chemistry ,Drug development ,Drug Design ,030220 oncology & carcinogenesis ,Rabbits - Abstract
(d)-Glucosamine and other nutritional supplements have emerged as safe alternative therapies for osteoarthritis, a chronic and degenerative articular joint disease. N-acetyl-(d)-glucosamine, a compound that can be modified at the N position, is considered to improve the oral bioavailability of (d)-glucosamine and has been proven to possess greater in vitro chondroprotective activity compared with the parent agent. In this study, to further utilize these properties, we focus on the modification of the N position with a benzenesulfonyl and different isoxazole formyl groups. Among these compounds, the 3-(2-chlorobenzene)-5-methyl-isoxazole formyl chloride and p-methoxybenzenesulfonyl chloride modifying structures proved to be the most active of the series and efficiently processed the chondrocytes in vitro. These novel N-position substitution compounds may represent promising leads for osteoarthritis drug development.
- Published
- 2016